Back to Search
Start Over
CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All.
- Source :
-
JAMA: Journal of the American Medical Association . 8/25/2020, Vol. 324 Issue 8, p747-749. 3p. - Publication Year :
- 2020
-
Abstract
- The article focuses on the results of the TAILOR-PCI randomized study examining a clinical decision strategy that depends on CYP2C19 genotyping to guide antiplatelet drug assignment following percutaneous coronary interventions. Study subjects received clopidogrel without initial genetic testing while another group of subjects received clopidogrel versus ticagrelor or prasugel. It suggests the use of a personalized medicine approach that involved genotyping for therapeutic interventions.
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 324
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- JAMA: Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- 145369046
- Full Text :
- https://doi.org/10.1001/jama.2020.13094